Products
Icariin derivative
Another name：3,7-bis(2-hydroxyethyl)icaritin
CasNo: 1067198-74-6 Purity： ≥98% Molecular Structure： C25H28O8
Icariin derivative Basic Product Information
| Product Name | Icariin derivative | CAS | 1067198-74-6 |
| Synonyms | 3,7-bis(2-hydroxyethyl)icaritin | Molecular Formula | C25H28O8 |
| EINECS Number | / | Molecular Structure | |
| Appearance | Yellow powder |
 |
|
| Purity | ≥98% | ||
| Supply Ability | 100kg / Per Month | ||
Icariin derivative Quality documents
Icariin derivative Appearance/Package/Shipping/Storage
Package
1g-500g/bottle ,500g-1kg/Aluminum foil bag ,10KG-100KG/Cardboard drum;
Storage condition
4℃ refrigerated, sealed, away from light
Icariin derivative Application
Used in industrial production, content supplementation, identification, pharmacological experiments
Icariin derivative literature
3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats
Lan, Tao-Hua,Chen, Xiao-Ling,Wu, Yun-Shan,Qiu, Hui-Liang,Li, Jun-Zhe,Ruan, Xin-Min,Xu, Dan-Ping,Lin, Dong-Qun
, p. 102 - 111 (2018)
Pulmonary arterial hypertension (PAH) is a chronic progressive disease which leads to elevated pulmonary arterial pressure and right heart failure. 3,7-Bis(2-hydroxyethyl)icaritin (ICT), an icariin derivatives, was reported to have potent inhibitory activ
Synthesis and cancer cell growth inhibitory activity of icaritin derivatives
Wang, Chen,Wu, Ping,Shi, Jing-Fang,Jiang, Zi-Hua,Wei, Xiao-Yi
, p. 139 - 150 (2015)
Abstract A series of icaritin derivatives bearing carboxylic acid or carboxylic ester groups are synthesized, and their in vitro cytotoxic activity against three cancer cell lines, MCF-7, MDA-MB-435s, and A549, are evaluated by MTT assay. Several derivati
Icaritin (ICT) derivative and preparation method and application thereof
-
Paragraph 0035-0039, (2019/11/04)
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to an icaritin (ICT) derivative shown as the formula (II), a pharmacologically-allowable salt and preparation method of the ICT derivative, and application of the ICT
Icaritin (ICT) derivative and preparation method and application thereof
-
Paragraph 0038-0041, (2019/11/04)
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to an icaritin (ICT) derivative shown as the formula (I), a pharmacologically-allowable salt and preparation method of the ICT derivative, and application of the ICT
Herba Epimedii glycoside compound and use thereof
-
Paragraph 0218; 0219; 0220; 0221; 0222, (2017/08/24)
The invention relates to an icariin compound and an application of the icariin compound in preparing medicines for preventing and treating fracture and osteoporosis. Particularly, the invention relates to the compound shown in a general formula (I) in the specification, a stereisomer, a stereomer, a tautomer, oxynitrides, hydrates, solvates, metabolites, and pharmaceutically acceptable salts or prodrugs thereof, wherein the variables are defined in the specification. The invention further relates to use of the compound, the stereisomer, the stereomer, the tautomer, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or salt of prodrugs thereof as medicines, particularly use in preparing medicines for preventing and treating fracture and osteoporosis.
Icariin derivative Upstream and downstream
1067198-74-6 Upstream product
113558-15-9
icariside II
540-51-2
2-bromoethanol
118525-40-9
icaritin
1067198-74-6 Downstream Products
Related Products
Please leave us a message or contact us using the following methods. We will reply to you as soon as possible and provide you with the most sincere service, thank you.
Hangzhou Office： Hangzhou Office:Suite#210A,No.1 Building, No.182 Zhaohui Road, Xiacheng District, Hangzhou City, Zhejiang Province,China.
Tel： +(86) 0571 8716 2326
Fax： +(86) 571 8719 1975
Phone： +(86) 177 6713 0763
Email： sales@kaimosi.com
WhatsApp： +(86)177 6713 0763
